Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Role of the actuary in LGPS contribution rate adjustments
Earlier this year the Kensington & Chelsea Borough Pension Fund caused something of a stir by setting a zero employer contribution rate against the ad
Cyber Insurance the Realities vs Myths putting SMEs at risk
There is now a widening gap between the exposure and cyber threats SMEs face and the defences that are in place to protect them. But despite smaller b
There is a need to complicate, our puts are short
Corporate bond spreads have continued to tighten, leaving substantially less upside in public IG than before. The US market recently hit the lowest it

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.